ATE515270T1 - Phep, eine aminosäurepermease von staphylococcus aureus - Google Patents

Phep, eine aminosäurepermease von staphylococcus aureus

Info

Publication number
ATE515270T1
ATE515270T1 AT05732793T AT05732793T ATE515270T1 AT E515270 T1 ATE515270 T1 AT E515270T1 AT 05732793 T AT05732793 T AT 05732793T AT 05732793 T AT05732793 T AT 05732793T AT E515270 T1 ATE515270 T1 AT E515270T1
Authority
AT
Austria
Prior art keywords
phep
amino acid
staphylococcus aureus
acid permease
antigenic polypeptides
Prior art date
Application number
AT05732793T
Other languages
English (en)
Inventor
Simon J Foster
Original Assignee
Absynth Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Absynth Biologics Ltd filed Critical Absynth Biologics Ltd
Application granted granted Critical
Publication of ATE515270T1 publication Critical patent/ATE515270T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT05732793T 2004-04-29 2005-04-08 Phep, eine aminosäurepermease von staphylococcus aureus ATE515270T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0409559.2A GB0409559D0 (en) 2004-04-29 2004-04-29 Polypeptide
PCT/GB2005/001384 WO2005105845A2 (en) 2004-04-29 2005-04-08 Phep, an amino acid permease of staphylococcus aureus

Publications (1)

Publication Number Publication Date
ATE515270T1 true ATE515270T1 (de) 2011-07-15

Family

ID=32408236

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05732793T ATE515270T1 (de) 2004-04-29 2005-04-08 Phep, eine aminosäurepermease von staphylococcus aureus

Country Status (11)

Country Link
US (2) US7740869B2 (de)
EP (1) EP1740206B1 (de)
JP (1) JP4906713B2 (de)
CN (1) CN1988917A (de)
AT (1) ATE515270T1 (de)
AU (1) AU2005238265B2 (de)
CA (1) CA2564596A1 (de)
DK (1) DK1740206T3 (de)
ES (1) ES2369087T3 (de)
GB (1) GB0409559D0 (de)
WO (1) WO2005105845A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0917685D0 (en) * 2009-10-09 2009-11-25 Absynth Biologics Ltd Antigenic polypeptide
GB201106162D0 (en) * 2011-04-12 2011-05-25 Absynth Biologics Ltd Combination vaccine
GB201206366D0 (en) * 2012-04-11 2012-05-23 Absynth Biologics Ltd Bacterial vaccine
US9777076B2 (en) 2012-07-16 2017-10-03 Pfizer Inc. Saccharides and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US6593114B1 (en) * 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus

Also Published As

Publication number Publication date
JP2008501318A (ja) 2008-01-24
EP1740206A2 (de) 2007-01-10
GB0409559D0 (en) 2004-06-02
WO2005105845A2 (en) 2005-11-10
US20080057065A1 (en) 2008-03-06
JP4906713B2 (ja) 2012-03-28
WO2005105845A3 (en) 2006-03-16
EP1740206B1 (de) 2011-07-06
ES2369087T3 (es) 2011-11-25
AU2005238265B2 (en) 2011-08-18
AU2005238265A1 (en) 2005-11-10
CA2564596A1 (en) 2005-11-10
CN1988917A (zh) 2007-06-27
US8168204B2 (en) 2012-05-01
DK1740206T3 (da) 2011-10-17
US7740869B2 (en) 2010-06-22
US20110171237A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
EA200501524A1 (ru) Антитела против амилоида, композиции, способы и применения
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
CY1119106T1 (el) Αντισωματα εναντι masp-2
ATE542829T1 (de) Impfstoff
SE0301653D0 (sv) Novel compounds
ATE426412T1 (de) Adjuvante influenza-vakzine
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
AR032231A1 (es) Nuevas proteinas insecticidas de bacillus thuringiensis
DK1618128T3 (da) Tuberkulosevaccine med forbedret effektivitet
CY1112014T1 (el) Συνθεσεις αντιβακτηριακων εμβολιων
WO2008052173A8 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
DK1409692T3 (da) Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine
ATE461710T1 (de) Nipah-virus-impfstoffe
EP1423137A4 (de) Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
EA200601219A1 (ru) Новые конденсированные пирролокарбазолы
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
TW200508246A (en) Anti-dengue virus antibodies, compositions, methods and uses
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
EA200702254A1 (ru) Вакцинная композиция, содержащая в-субъединицу термолабильного токсина e.coli и антиген и адъювант
GB2568440A (en) Modified factor H binding protein
ATE515270T1 (de) Phep, eine aminosäurepermease von staphylococcus aureus
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties